Disturbed trophoblast transition links preeclampsia progression from placenta to the maternal syndrome

Olivia Nonn, Olivia Debnath, Daniela S. Valdes, Katja Sallinger, Kerim Secener, Sandra Haider, Cornelius Fischer, Sebastian Tiesmeyer, Jose Nimo, Thomas Kuenzer, Theresa Maxian, Martin Knöfler, Philipp Karau, Hendrik Bartolomaeus, Thomas Kroneis, Alina Frolova, Lena Neuper, Nadine Haase, Kristin Kräker, Sarah Kedziora, Désirée Forstner, Stefan Verlohren, Christina Stern, Fabian Coscia, Meryam Sugulle, Stuart A. Jones, Basky Tilaganathan, Roland Eils, Berthold Huppertz, Amin El‐Heliebi, Anne Cathrine Staff, Dominik N. Müller, Ralf Dechend, Martin Gauster, Naveed Ishaque, Florian HersebioRxiv 2022 · DOI

TL;DR

This study reveals that pre-eclampsia (PE) originates from a disrupted early developmental process in placental cells (trophoblasts), leading to premature senescence and the release of signaling molecules that affect the mother. The findings identify key molecular players and potential early biomarkers for PE, offering hope for improved diagnosis and intervention.

What Problem Does This Paper Address?

Pre-eclampsia (PE) is a severe pregnancy complication characterized by high blood pressure and other issues, posing risks to both mother and child. Despite its prevalence, the exact causes and early warning signs remain elusive, making effective screening and treatment challenging. Current therapies are limited, and diagnosis often occurs late in pregnancy when damage may already be irreversible. This paper aims to bridge this knowledge gap by investigating the very early stages of PE development, specifically focusing on how placental cells transition and differentiate, and how this process might be disrupted in PE.

Methods

The researchers employed a multi-pronged approach combining cutting-edge technologies:

  • Single-nucleus RNA sequencing (snRNA-seq): This allowed them to analyze gene expression at a single-cell level in placental tissues from early and late pregnancy, as well as from PE and healthy pregnancies.
  • Spatial transcriptomics and proteomics: These techniques helped them understand the spatial organization of cells and their molecular profiles within the placental tissue, providing context to the gene expression data.
  • In vitro signaling analyses: Mechanistic studies using cultured cells helped to validate findings and explore the functional consequences of identified molecular changes.
  • Longitudinal cohort study: They followed women from early pregnancy to delivery to validate early pregnancy biomarkers.
  • Computational modeling: Techniques like diffusion pseudotime and network analysis were used to reconstruct cell differentiation trajectories and identify key regulatory pathways.

Datasets

The study utilized placental tissue samples from:

  • Healthy pregnancies: Collected in the first trimester (5-10 weeks gestation) and at term (≥38 weeks gestation).
  • Early-onset pre-eclampsia (eoPE) pregnancies: Collected before 34 weeks gestation.
  • Validation cohorts: Samples from Graz and Oslo were used to confirm findings.

Key Insights and Ideas

  • PE starts early: The study strongly suggests that PE is not just a late-pregnancy complication but originates from a fundamental disruption in the early development and differentiation of placental cells.
  • Trophoblast transition is key: A critical event is the disturbed transition of villous trophoblast cells, leading to premature senescence.
  • Senescence as a driver: This premature senescence in trophoblasts appears to be a major contributor to the pathology, releasing signaling molecules that impact the maternal system.
  • p300 as a central regulator: The transcriptional coactivator p300 emerges as a key player in driving this aberrant differentiation and senescence.
  • Early maternal signaling: The placenta's distress signals, particularly through senescence markers like Activin A, can be detected in maternal serum even before clinical symptoms appear, offering a window for early diagnosis.

Key Results

  • Identified a novel "juvenile STB" (syncytiotrophoblast) cell state characterized by specific gene expression patterns.
  • Discovered that the transcriptional coactivator p300 is dysregulated in PE and plays a crucial role in the aberrant transition of trophoblast cells.
  • Showed that senescent trophoblasts release factors (SASP) that interact with maternal vasculature, potentially explaining the systemic nature of PE.
  • Validated Activin A and GDF15 as early pregnancy biomarkers that can predict PE risk, even when current screening algorithms underestimate it.
  • Demonstrated that these early pregnancy biomarkers, when combined with uterine artery pulsatility index, improve PE prediction.

Limitations and Future Work

  • Longitudinal data integration: While the study used a longitudinal cohort for validation, further integration of biospecimens across a longer gestational time is needed to fully interpolate PE development and progression.
  • Computational modeling: The authors acknowledge that further computational work is needed to interpolate further important time frames in PE development and progression.
  • Therapeutic development: The identified biomarkers and pathways provide a foundation for developing new therapeutic approaches, but this requires further research and clinical trials.
  • Mechanistic understanding: While the study highlights key molecular players, further investigation into the precise mechanisms by which these factors contribute to PE pathogenesis is warranted.
  • Focus on early intervention: The authors suggest that future research and precision medicine in pregnancy should focus on targeting the disturbed fetal trophoblast transition to prevent PE and its long-term consequences.

Summary updated

Abstract

Summary Pre-eclampsia (PE) is a syndrome that affects multiple organ systems and is the most severe hypertensive disorder in pregnancy. It frequently leads to preterm delivery, maternal and fetal morbidity and mortality and life-long complications 1 . We currently lack efficient screening tools 2, 3 and early therapies 4, 5 to address PE. To investigate the early stages of early onset PE, and identify candidate markers and pathways, we performed spatio-temporal multi-omics profiling of human PE placentae and healthy controls and validated targets in early gestation in a longitudinal clinical cohort. We used a single-nuclei RNA-seq approach combined with spatial proteo- and transcriptomics and mechanistic in vitro signalling analyses to bridge the gap from late pregnancy disease to early pregnancy pathomechanisms. We discovered a key disruption in villous trophoblast differentiation, which is driven by the increase of transcriptional coactivator p300, that ultimately ends with a senescence-associated secretory phenotype (SASP) of trophoblasts. We found a significant increase in the senescence marker activin A in preeclamptic maternal serum in early gestation, before the development of clinical symptoms, indicating a translation of the placental syndrome to the maternal side. Our work describes a new disease progression, starting with a disturbed transition in villous trophoblast differentiation. Our study identifies potential pathophysiology-relevant biomarkers for the early diagnosis of the disease as well as possible targets for interventions, which would be crucial steps toward protecting the mother and child from gestational mortality and morbidity and an increased risk of cardiovascular disease later in life.
BibTeX
@misc{nonn2022disturbed,
  author = {Olivia Nonn and Olivia Debnath and Daniela S. Valdes and Katja Sallinger and Kerim Secener and Sandra Haider and Cornelius Fischer and Sebastian Tiesmeyer and Jose Nimo and Thomas Kuenzer and Theresa Maxian and Martin Knöfler and Philipp Karau and Hendrik Bartolomaeus and Thomas Kroneis and Alina Frolova and Lena Neuper and Nadine Haase and Kristin Kräker and Sarah Kedziora and Désirée Forstner and Stefan Verlohren and Christina Stern and Fabian Coscia and Meryam Sugulle and Stuart A. Jones and Basky Tilaganathan and Roland Eils and Berthold Huppertz and Amin El‐Heliebi and Anne Cathrine Staff and Dominik N. Müller and Ralf Dechend and Martin Gauster and Naveed Ishaque and Florian Herse},
  title = {{Disturbed trophoblast transition links preeclampsia progression from placenta to the maternal syndrome}},
  year = {2022},
  doi = {10.1101/2022.10.10.511539},
  howpublished = {bioRxiv},
}
Figure